KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Equity Average (2016 - 2025)

Neogenomics' Equity Average history spans 15 years, with the latest figure at $837.4 million for Q4 2025.

  • For Q4 2025, Equity Average fell 7.49% year-over-year to $837.4 million; the TTM value through Dec 2025 reached $837.4 million, down 7.49%, while the annual FY2025 figure was $869.5 million, 5.69% down from the prior year.
  • Equity Average reached $837.4 million in Q4 2025 per NEO's latest filing, down from $846.2 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $1.1 billion in Q3 2021 to a low of $769.0 million in Q1 2021.
  • Average Equity Average over 5 years is $959.1 million, with a median of $948.1 million recorded in 2023.
  • Peak YoY movement for Equity Average: soared 73.07% in 2021, then fell 10.44% in 2022.
  • A 5-year view of Equity Average shows it stood at $1.1 billion in 2021, then fell by 10.44% to $1.0 billion in 2022, then dropped by 6.07% to $944.5 million in 2023, then decreased by 4.15% to $905.3 million in 2024, then decreased by 7.49% to $837.4 million in 2025.
  • Per Business Quant, the three most recent readings for NEO's Equity Average are $837.4 million (Q4 2025), $846.2 million (Q3 2025), and $871.2 million (Q2 2025).